A new Advfn thread13 Aug 2020 23:12
have monitored this company for a long time. This company was set up in 2006. The company shares have been consolidated twice due to severe dilutions, hence those former directors have been removed. Valirx has spent millions of pounds to develop VAL 201 VAL 301 and VAL 401. Yet Valirx market cap is only £7m ( at the time of writing )
VAL 201 - treatment of metastatic prostate cancer phase I/ll - result due in few weeks
VAL 401 - treatment of late stage small cell lung cancer phase II/III
VAL 301 - treatment of endometriosis - pre clinical stage.
Many companies with advance clinical trials like VAL have market cap of more than £50m. The treatment of prostate/lung cancer worth billion of pounds worldwide.
The new management team is competent and will maximise shareholders and stakeholders values by minimising share dilution and collaborate with other pharma to develop VAL treatment compounds.
Good luck.